Acute Coronary Syndrome Therapeutic Market by Types (Vial Unstable Angina, ST-elevation Myocardial Infarction, and Non-ST-elevation Myocardial Infarction), Drugs (Statins Drug, Antithrombotic Drug, Antihypertensive Drug, and Others), and Regions (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2021 – 2028

The global acute coronary syndrome therapeutic market size is projected to expand at a considerable CAGR during the forecast period, 2021–2028. The growth of the market is attributed to the technological advancement in the area of coronary syndrome, new product launch with better accuracy and efficacy, and increasing disposal income of the population.

Acute coronary syndrome (ACS) refers to the sudden reduced of blood flow to the heart and a spectrum of clinical symptoms ranging from unstable angina to ST-segment elevation myocardial infarction, and non–ST-segment elevation myocardial infarction. Furthermore, a blood clot occurs when a plaque deposit splits. This clot prevents blood from flowing to the cardiac muscles. When the oxygen supply is insufficient, cells of the heart will die gradually. A heart attack occurs when cells die, causing damage to muscular tissues (myocardial infarction). ACS causes significant chest pain or discomfort. It is a medical emergency that necessitates immediate diagnosis and treatment. The main objective of the treatment is to improve blood flow, manage complications, and prevent future difficulties. The most prevalent symptom is chest pain or discomfort. However, depending on age, sex, and other medical issues; coronary syndrome’s signs and symptoms may differ dramatically in case of women, adults, and diabetic patients.

The outbreak of COVID-19 pandemic is an unmatched global public health emergency that has impacted almost every industry and the longstanding effect are anticipated to influence the industry growth during the forecast period. As hospitals are packed with COVID-19 patients, the number of people visiting to hospitals are reduced significantly and only emergency treatments are being performed. However, regulatory authorities are utilizing methods to speed approval of diagnostic products. Healthcare industry has moved strategically to develop rapid tests for COVID-19, try to lowering the impact of COVID-19 on their operational capabilities, and sustain their revenues.

Market Trends, Drivers, Restraints, and Opportunities

• Growing geriatric population and rising cases of chronic illness especially cardiovascular disease are expected to propel the market growth.
• Increasing prevalence of unhealthy life style causes various disease such as high cholesterol and diabetes. This is anticipated to fuel the market growth.
• Rising awareness among the people related to coronary syndrome is projected to upsurge the market growth.
• Many healthcare companies and research institutes are collaborating to develop advanced therapies for coronary syndrome treatment. This is expected to fuel the market growth in coming years.
• Delaying in product approvals and stringent government regulations are some of the restraining factors challenging the market growth.
• Favorable government policies especially in reimbursement system and improving healthcare infrastructure in developing economies are great opportunities for the acute coronary syndrome treatment market in the coming years.

Scope of the Report

The report on the global acute coronary syndrome therapeutic market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Market Segment Insights

Unstable angina segment is expected to grow at a rapid pace

Based on types, the global acute coronary syndrome therapeutic market is segmented into vial unstable angina, ST-elevation myocardial infarction, and non-ST-elevation myocardial infarction. The unstable angina segment is expected to grow at a rapid pace during the forecast period due to the increasing disposable income in emerging economies. Unstable angina is caused by a lack of blood flow and oxygen in the body, which can lead to a heart attack. On the other hand, when blood clots partially clog the coronary arteries, non ST elevation myocardial infarction occurs. On the other hand, the rising participation of new players and increasing number of clinical trial registrations is expected to fuel the segment growth in the coming years.

Anti-hypertensive drugs segment is projected to expand at a considerable CAGR

On the basis of drugs, the market is segregated as statins drug, antithrombotic drug, antihypertensive drug, and others. The anti-hypertensive drugs segment is projected to expand at a considerable CAGR during the forecast period owing to the increasing number of patients suffering from hypertension, changing lifestyle such as dietary habits, growing adoption of generic drug versions, and rising prevalence of chronic diseases. Antihypertensive drugs are segmented into several categories, each of which has the ability to lower blood pressure in different ways. Thereby, these drugs can prevent several complications associated with high blood pressure such as stroke and myocardial infarction. Thus, it is anticipated to propel the segment growth.

On the other hand, the unavailability of promising treatment options with fewer side effects and complications associated with uncontrolled high blood pressure are key restraints for the segment growth.

North America is anticipated to constitute a key market share

In terms of regions, the global acute coronary syndrome therapeutic market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is anticipated to constitute a key market share during the forecast period owing to the well-established healthcare infrastructure, which has led to a rise in the treatment of acute coronary syndrome, and ongoing awareness campaign conducted by various organizations.

However, the market of Asia Pacific is projected to register moderate revenue share in the coming years due to the increasing number of outsourcing, expanding medical tourism, and increasing disposable income in the region.

Segments

• Vial Unstable Angina
• ST-elevation Myocardial Infarction
• Non-ST-elevation Myocardial Infarction

• Statins Drug
• Antithrombotic Drug
• Antihypertensive Drug
• Others

• Asia Pacific
• North America
• Latin America
• Europe
• Middle East & Africa

• Artery Therapeutics
• XOMA Corp.
• Athera Biotechnologies
• Pfizer Inc.
• Cardiome Pharma Corp.
• Cerenis Therapeutics Holding SA
• Esperion Therapeutics
• GlaxoSmithLline Plc
• Lee’s Pharma Corp.
• Bayer AG
• Teva Pharmaceutical Industries Ltd.
• Vitae Pharmaceuticals, Inc.
• The Medicines Co.
• Arena Pharmaceuticals.

Competitive Landscape

Some of the key competitors competing in the market are Artery Therapeutics; XOMA Corp.; Athera Biotechnologies; Pfizer Inc.; Cardiome Pharma Corp.; Cerenis Therapeutics Holding SA; Esperion Therapeutics; GlaxoSmithLline Plc; Lee’s Pharma Corp.; Bayer AG; Teva Pharmaceutical Industries Ltd.; Vitae Pharmaceuticals, Inc.; The Medicines Co.; and Arena Pharmaceuticals.

In order to gain larger revenue share and secure their market position, several companies are implementing various marketing strategies such as merger & acquisition, regional expansion, research & development, and new product launching. Amgen’s Repatha has performed ten phases of clinical trials program named PROFICIO for testing the patient's low-density lipoprotein cholesterol (LDL-C) and cardiovascular results. On the other hand, Merck is developing MK-0859 for the treatment of hypercholesterolemia and cardiovascular disease.